CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BMY

Nivolumab in combination with Urelumab

Phase 2
Bristol-Myers Squibb Company (BMY)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q3 '27
BMYPhase 2

Nivolumab in combination with Urelumab Phase 2 Est. Readout

Nivolumab in combination with Urelumab
Q3 2027~Q
CT.gov
00%
Competitive Landscape

0 competitors in Urothelial Carcinoma

View Full Landscape
Drug Information

Target Indication

Urothelial Carcinoma

Clinical Trial

NCT02845323

Last updated: 11/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.